DSpace Repository

Related Impurities HPLC Method Development & Validation for drug combinations: Olmesartan Medoxomil, Chlorthalidone & Cilnidipine

Show simple item record

dc.contributor.author Shah, P.
dc.contributor.author Dhadhuk, B
dc.date.accessioned 2024-11-19T06:48:57Z
dc.date.available 2024-11-19T06:48:57Z
dc.date.issued 2020
dc.identifier.citation Shah, P., & Dhadhuk, B. (2020). Related impurities high-performance liquid chromatography method development and validation for drug combinations: olmesartan medoxomil, chlorthalidone and cilnidipine. Int J of Pharma Scien and Drug Research, 12, 1-10. en_US
dc.identifier.uri http://10.9.150.37:8080/dspace//handle/atmiyauni/1677
dc.description.abstract The LC-MS compatible, stability-indicating, specific, linear, accurate, sensitive with less run-time RP-HPLC related impurities method has been developed for Olmesartan Medoxomil, Chlorthalidone, and Cilnidipine drug combinations. And the method has been validated according to ICH and US-FDA guidelines. The separation was performed by using Hypersil-BDS Thermo-Scientific, C/18 (12.5 cm, 4.6mm, 5-micron particle size) column. Mobile phase-I was prepared by mixing 3.85 gm Ammonium acetate in HPLC water and adjust pH-5.0 by using diluted acetic acid. Acetonitrile was taken as Mobile phase-B. Initial mobile phase ratio (55:45,v/v) was adjusted for Mobile phase-A: Mobile phase-B followed by gradient program. Other chromatographic conditions such as column temperature 25 degrees, flow rate 1.0 mL/minutes with the detection wavelength at 260 nm. The retention time for Chlorthalidone Impurity A, Olmesartan, Olmesartan Medoxomil Impurity A, were found about 2.7, 3.3, and 7.2 minutes, with a total run time of 18.0 minutes. The linearity calibration plot was performed andfound linear relationship over the concentration range of 1.25(LOQ)–18.75 μg/ml, 3.6(LOQ)–60.0 μg/ml,3.6(LOQ)–60.0 μg/ml respectively for Chlorthalidone Impurity-A, Olmesartan and Olmesartan MedoxomilImpurity A respectively. The LOD and LOQ were found 0.4 ppm (μg/ml) & 1.2 ppm (μg/ml), 1.2 ppm (μg/ml) & 3.5 ppm (μg/ml), 1.1 ppm (μg/ml) & 3.3 ppm (μg/ml) for Chlorthalidone Impurity A, Olmesartanand Olmesartan Medoxomil Impurity A respectively. The accuracy was determined by recovery studies was found between 90.0-110.0%. The developed analytical method has been validated for lod-loq specificity, linearity, accuracy, precision, robustness, and ruggedness, which were well within the acceptance limit as per ICH guidelines. All the degradation products generated by stress conditions were found to be well separated from one another (all drug components and impurities). The developed method with shorter runtime was successfully implemented for routine quality control and stability analysis to checkthe quality of olmesartan medoxomil, chlorthalidone, and cilnidipine drug combinations. en_US
dc.language.iso en en_US
dc.publisher Int J of Pharma Scien and Drug Research en_US
dc.subject Chlorthalidone, Cilnidipine en_US
dc.subject HPLC en_US
dc.subject ICH guidelines en_US
dc.subject Olmesartan Medoxomil en_US
dc.subject Olmesartan Medoxomil en_US
dc.title Related Impurities HPLC Method Development & Validation for drug combinations: Olmesartan Medoxomil, Chlorthalidone & Cilnidipine en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account